Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT06633016

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

Led by Autobahn Therapeutics, Inc. · Updated on 2026-01-20

230

Participants Needed

50

Research Sites

88 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening, approximately 35 days 2. 42-day Treatment Period 3. 2-week post dose Safety Follow-up Period 4. 6-month postdose targeted safety follow-up period

CONDITIONS

Official Title

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 65 years
  • Meets DSM-5 criteria for Major Depressive Disorder with a current episode lasting more than 6 weeks and up to 18 months
  • Hamilton Anxiety Rating Scale score of 22 or less
  • Montgomery-Asberg Depression Rating Scale score greater than 24 at screening and baseline
  • Taking a single SSRI or SNRI antidepressant at an adequate dose for at least 6 weeks with inadequate response
  • Stable antidepressant dose for at least 4 weeks prior to screening and throughout the study
Not Eligible

You will not qualify if you...

  • History of schizophrenia, psychotic disorders, major depressive disorder with psychotic features, bipolar I or II disorder, cyclothymic disorder, delirium, dementia, amnestic or cognitive disorders
  • Current or recent (within 2 years) diagnosis of obsessive-compulsive disorder, PTSD, panic disorder, or eating disorders
  • Primary diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder
  • Current or recent (within 2 years) self-injurious behavior
  • Failure of more than 2 SSRI/SNRI antidepressant treatments during current episode
  • Failure to respond to thyroid hormone augmentation for depression
  • New or changed psychotherapy within 8 weeks prior to screening
  • Suicidal at screening or baseline
  • Uncontrolled significant medical disorders within 3 months prior to screening
  • History of thyroid disease or multiple endocrine neoplasia syndrome
  • Diagnosis of epilepsy or history of convulsions
  • Pregnant, planning pregnancy, or breastfeeding
  • Prior use of psychedelics, ketamine, or esketamine for depression
  • Recent use (within 4 weeks) of other augmentation agents for depression
  • Current or prior treatment for hypothyroidism
  • Use of biotin within 14 days prior to Day 1 through last visit
  • Use of strong cytochrome P450 3A4 inhibitors or inducers
  • Substance abuse or illicit drug use within 1 year prior to screening
  • History or presence of cataracts, glaucoma, inflammatory eye disease, or prior eye surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 50 locations

1

Autobahn Site #131

Birmingham, Alabama, United States, 35294

Actively Recruiting

2

Autobahn Site #132

Chandler, Arizona, United States, 85224

Active, Not Recruiting

3

Autobahn Site #116

Phoenix, Arizona, United States, 85102

Active, Not Recruiting

4

Autobahn Site #136

Tucson, Arizona, United States, 85704

Withdrawn

5

Autobahn Site #150

Anaheim, California, United States, 92805

Actively Recruiting

6

Autobahn Site #113

Encino, California, United States, 91316

Withdrawn

7

Autobahn Site #133

Encino, California, United States, 91316

Withdrawn

8

Autobahn Site #124

Glendale, California, United States, 91206

Actively Recruiting

9

Autobahn Site #140

Long Beach, California, United States, 90807

Actively Recruiting

10

Autobahn Site #121

Los Alamitos, California, United States, 90720

Withdrawn

11

Autobahn Site #117

Newport Beach, California, United States, 92660

Withdrawn

12

Autobahn Site #106

Oceanside, California, United States, 92056

Active, Not Recruiting

13

Autobahn Site #152

Orange, California, United States, 92866

Actively Recruiting

14

Autobahn Site #151

Rancho Cucamonga, California, United States, 91730

Actively Recruiting

15

Autobahn Site #119

San Jose, California, United States, 95124

Actively Recruiting

16

Autobahn Site #126

Walnut Creek, California, United States, 94596

Actively Recruiting

17

Autobahn Site #149

West Covina, California, United States, 91790

Actively Recruiting

18

Autobahn Site #122

Cromwell, Connecticut, United States, 06416

Actively Recruiting

19

Autobahn Site #108

Brandon, Florida, United States, 33511

Actively Recruiting

20

Autobahn Site #110

Hialeah, Florida, United States, 33012

Actively Recruiting

21

Autobahn Site #101

Jacksonville, Florida, United States, 32256

Actively Recruiting

22

Autobahn Site #139

Lake City, Florida, United States, 32055

Active, Not Recruiting

23

Autobahn Site #111

Miami, Florida, United States, 33144

Actively Recruiting

24

Autobahn Site #141

Miami, Florida, United States, 33157

Active, Not Recruiting

25

Autobahn Site #147

Miami Gardens, Florida, United States, 33014

Actively Recruiting

26

Autobahn Site #102

Orlando, Florida, United States, 32822

Active, Not Recruiting

27

Autobahn Site #148

Tampa, Florida, United States, 33629

Actively Recruiting

28

Autobahn Site #123

Atlanta, Georgia, United States, 30328

Active, Not Recruiting

29

Autobahn Site #112

Decatur, Georgia, United States, 30030

Actively Recruiting

30

Autobahn Site #142

Peachtree Corners, Georgia, United States, 30071

Actively Recruiting

31

Autobahn Site #120

Savannah, Georgia, United States, 31405

Active, Not Recruiting

32

Autobahn Site #154

Elgin, Illinois, United States, 60123

Active, Not Recruiting

33

Autobahn Site #137

Boston, Massachusetts, United States, 02130

Actively Recruiting

34

Autobahn Site #138

Watertown, Massachusetts, United States, 02472

Active, Not Recruiting

35

Autobahn Site #127

Saint Charles, Missouri, United States, 63304

Actively Recruiting

36

Autobahn Site #130

Las Vegas, Nevada, United States, 89121

Withdrawn

37

Autobahn Site #129

Berlin, New Jersey, United States, 08009

Actively Recruiting

38

Autobahn Site #105

Brooklyn, New York, United States, 11229

Actively Recruiting

39

Autobahn Site #134

Brooklyn, New York, United States, 11235

Actively Recruiting

40

Autobahn Site #125

New York, New York, United States, 10022

Active, Not Recruiting

41

Autobahn Site #104

Staten Island, New York, United States, 10314

Actively Recruiting

42

Autobahn Site #109

Beachwood, Ohio, United States, 44122

Actively Recruiting

43

Autobahn Site #107

Oklahoma City, Oklahoma, United States, 73112

Actively Recruiting

44

Autobahn Site #128

North Charleston, South Carolina, United States, 29405

Active, Not Recruiting

45

Autobahn Site #153

Beaumont, Texas, United States, 77701

Actively Recruiting

46

Autobahn Site #146

San Antonio, Texas, United States, 78215

Actively Recruiting

47

Autobahn Site #144

Sherman, Texas, United States, 75092

Actively Recruiting

48

Autobahn Site #159

Orem, Utah, United States, 84058

Actively Recruiting

49

Autobahn Site #145

Fairfax, Virginia, United States, 22030

Actively Recruiting

50

Autobahn Site #143

Bellevue, Washington, United States, 98007

Actively Recruiting

Loading map...

Research Team

A

Ashlee Heldreth, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here